Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R

Authors

Rahul Lakhotia, National Cancer Institute
Kieron Dunleavy, Georgetown University
Jeremy S Abramson, Massachusetts General Hospital Cancer Center
Brian K Link, University of Iowa
Bayard L Powell, Wake Forest University
Christopher Melani, National Cancer Institute
Andrea N Lucas, National Cancer Institute
Seth M Steinberg, National Institutes of Health
Jonathan W Friedberg, University of Rochester
Brad S Kahl, Washington University School of Medicine in St. Louis
Richard F Little, National Cancer Institute
Nancy L Bartlett, Washington University School of Medicine in St. Louis
Ariela Noy, Memorial Sloan Kettering Cancer Center
Wyndham H Wilson, National Cancer Institute
Mark Roschewski, National Cancer Institute

Journal

Blood Advances

Publication Date

9-26-2023

Volume

7

Issue

18

First Page

5320

Last Page

5324

Document Type

Open Access Publication

DOI

10.1182/bloodadvances.2023010223

Rights and Permissions

Lakhotia R, Dunleavy K, Abramson JS, Link BK, Powell BL, Melani C, Lucas AN, Steinberg SM, Friedberg JW, Kahl BS, Little RF, Bartlett NL, Noy A, Wilson WH, Roschewski M. Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R. Blood Adv. 2023 Sep 26;7(18):5320-5324. doi: 10.1182/bloodadvances.2023010223. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution.

Recommended Citation

Lakhotia, Rahul; Dunleavy, Kieron; Abramson, Jeremy S; Link, Brian K; Powell, Bayard L; Melani, Christopher; Lucas, Andrea N; Steinberg, Seth M; Friedberg, Jonathan W; Kahl, Brad S; Little, Richard F; Bartlett, Nancy L; Noy, Ariela; Wilson, Wyndham H; and Roschewski, Mark, "Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R." Blood Advances. 7, 18. 5320 - 5324. (2023).
https://digitalcommons.wustl.edu/oa_4/2313